$2.07
-0.13 (-5.91%)
Open$2.22
Previous Close$2.20
Day High$2.22
Day Low$2.05
52W High$2.66
52W Low$0.40
Volume—
Avg Volume1.59M
Market Cap267.11M
P/E Ratio—
EPS$-1.49
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,143.0% upside
Current
$2.07
$2.07
Target
$25.73
$25.73
$15.89
$25.73 avg
$34.39
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.10M | 17.71M | 19.64M |
| Net Income | 3.87M | 3.06M | 4.04M |
| Profit Margin | 21.4% | 17.3% | 20.6% |
| EBITDA | 5.83M | 6.29M | 6.55M |
| Free Cash Flow | 3.85M | 4.93M | 3.44M |
| Rev Growth | +0.2% | -1.6% | +10.4% |
| Debt/Equity | 0.48 | 0.65 | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |